The success of recent initiatives to enhance drug discovery and development hinges on bridging the sociological divides that persist in the industry. Reflecting on the 50th issue of *Nature Reviews Drug Discovery*, the journal's original mission to foster communication between disciplines remains crucial. The pharmaceutical industry faces unprecedented challenges, including low approval rates for new molecular entities and weakened earnings. While companies are investing more in R&D and exploring various strategies, such as mergers and acquisitions and outsourcing, these efforts may only temporarily mask underlying issues. To reduce technological gaps, greater cooperation between disciplines and competitors is essential. Initiatives like the Predictive Safety Testing Consortium and the Center for Biomedical Innovation (CBI) aim to promote collaboration. However, true progress requires a significant shift in the sociology of drug discovery, particularly addressing the gap between academic and industry scientists. Both sectors must overcome stereotypes and recognize the value of external creativity and long-term commitment. Bridging these divides will require researchers to unite around scientific philosophies rather than forming specialized "tribes." Without such changes, the future of drug discovery and development remains uncertain.The success of recent initiatives to enhance drug discovery and development hinges on bridging the sociological divides that persist in the industry. Reflecting on the 50th issue of *Nature Reviews Drug Discovery*, the journal's original mission to foster communication between disciplines remains crucial. The pharmaceutical industry faces unprecedented challenges, including low approval rates for new molecular entities and weakened earnings. While companies are investing more in R&D and exploring various strategies, such as mergers and acquisitions and outsourcing, these efforts may only temporarily mask underlying issues. To reduce technological gaps, greater cooperation between disciplines and competitors is essential. Initiatives like the Predictive Safety Testing Consortium and the Center for Biomedical Innovation (CBI) aim to promote collaboration. However, true progress requires a significant shift in the sociology of drug discovery, particularly addressing the gap between academic and industry scientists. Both sectors must overcome stereotypes and recognize the value of external creativity and long-term commitment. Bridging these divides will require researchers to unite around scientific philosophies rather than forming specialized "tribes." Without such changes, the future of drug discovery and development remains uncertain.